Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is a performance beauty company that offers innovative and differentiated medical aesthetic products, with an established brand and 14% market share in the U.S. The company's cash-pay model and focus on millennials, combined with the recent launch of new products and plans for international expansion, position it for future growth. Its diverse product portfolio and strategic pricing flexibility mitigate potential risks and drive potential revenue growth, supporting our Buy rating and $13 price target.

Bears say

Evolus is facing a difficult market environment, with slowdowns in the last three major downturns and a recent weakening of the market for injectable neurotoxins. Despite its differentiated go-to-market strategy and established market share, the company's financials are concerning, with cash on hand and access to debt being the only saving grace. The recent launch of new products may provide some upside, but with weak market conditions and new competitors, the company's ability to achieve its long-term financial targets is uncertain.

Evolus (EOLS) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 5 analysts, Evolus (EOLS) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.